OncoMed Pharmaceuticals, Inc. OMED, +6.44% a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will provide a corporate update at two upcoming investor conferences.
- Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on September 5, 2018 at 9:40 am Eastern Time
- 20 [th] Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC in New York, NY on September 6, 2018 at 4:40 pm Eastern Time
To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit OncoMed's website at www.oncomed.com/invest/events.cfm. A replay of each presentation will be available for 30 days following the date of the event.
Read More: https://www.marketwatch.com/press-release/oncomed-to-present-at-two-upcoming-investor-conferences-in-september-2018-08-29
Via: Business Wire
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that it raised $132 million in a Series D equity financing. The round was led by new investor Mubadala Investment Company, Abu Dhabi’s leading investment company, active in numerous sectors and more than 30 countries around the world. Existing investors Baxter Ventures, the venture capital arm of Baxter International, Fidelity Management and Research Company, Partner Fund Management LP, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., and Warburg Pincus also participated in the equity round.
Via: WVU Medicine
MORGANTOWN, W.Va. – Surgeons at the WVU Heart and Vascular Institute are now offering a new minimally invasive treatment for patients with carotid artery disease.
TCAR (Transcarotid Artery Revascularization): The Next Step in the Evolution of Carotid Revascularization
Via: Endovascular Today
Since its introduction in the 1950s, carotid endarterectomy (CEA) has been considered the gold standard treatment option for carotid revascularization. However, in patients with high-risk anatomic and/or physiologic characteristics, CEA is associated with higher rates of adverse outcomes.1 Transfemoral carotid angioplasty and stenting (TF-CAS) was introduced over 2 decades ago as a potential alternative. However, its effectiveness compared to CEA remains unclear, and full adoption of TF-CAS has been hindered by a higher rate of periprocedural stroke.2